← All candidates
77 insider filings on record.
77 filings on record.
TVTXTravere Therapeutics, Inc.
NasdaqGM · Healthcare · $6.34B
$65.79
+1.55% · Sep 16
77 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 36 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$6.34B
Float
93.2M
99% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
11.9
Price / sales
10.7
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
72 more transactions on Pro →Context
Wall St
$58.36 avg target
-11.3% vs today · 14 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26$0.05 act+$0.11
Q4 '25$0.37 act−$0.00
Q3 '25$0.59 act+$0.67
Q2 '25$0.13 act+$0.09
Coverage
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?Insider Monkey · 06-13TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% UpsideStocktwits · 06-023 Stocks That May Be Priced Below Their Estimated Value In June 2026Simply Wall St. · 06-08Extreme Networks And 2 Other Stocks That Could Be Trading Below Their Estimated ValueSimply Wall St. · 06-03
The file stays open
77 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice